Gelonghui, March 20 | Saisheng Pharmaceutical (300485.SZ) announced that the company participated in the Beijing-Tianjin-Hebei “3+N” drug centralized procurement and centralized procurement work carried out by Guangzhou Trading Group Co., Ltd., according to the “Notice on Accomplishing the Implementation of the Ninth Batch of National Organization Collection and the Beijing-Tianjin-Hebei “3+N” Alliance Drug Centralized Procurement Results” issued by the Tianjin Municipal Medical Security Administration (Tianjin Pharmaceutical Collection [2024] No. 3) and the Guangzhou Public Resources Exchange Center “Notice on Selection/Alternative Results of Centralized Procurement”, the company's products sodium deoxynucleotide injection and arginine hydrochloride injection were selected separately.
赛升药业(300485.SZ)：脱氧核苷酸钠注射液和盐酸精氨酸注射液中选药品集中采购
Saisheng Pharmaceutical (300485.SZ): Centralized procurement of selected drugs from sodium deoxynucleotide injections and arginine hydrochloride injections
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.